SYNERGY™

Everolimus-Eluting Platinum Chromium Coronary Stent System

EVOLVE Short DAPT Trial – Shortened DAPT* Regimen, High Bleeding Risk (HBR) patients and SYNERGY Bioabsorbable Polymer (BP) Stent

EVOLVE Short DAPT Trial is studying 3-month DAPT in High Bleeding Risk (HBR) patients undergoing PCI with the SYNERGY BP-DES

Trial Design

Multicenter, single arm trial studying 2,009 patients with significant bleeding risks at over 110 global sites. 67% patients were elderly patients with age >= 75 years. Primary Endpoint will be collected from 1,484 patients eligible to discontinue their DAPT at 3-months.  

Clinical Outcomes at 3-Months

EVOLVE Short DAPT 3-month data provides encouraging insight into SYNERGY™ BP-DES performance in HBR patients1

Ischemic outcomes through 3 months were extremely favorable in this complex patient group:

  • Cardiac Death: 1.2%
  • MI: 1.4%
  • TLR 0.3%
  • Definite/probable ST: 0.3%

 

This data is very encouraging for this complex patient group with significant bleeding risk and we look forward to 15-month primary endpoint results to be reported in late 2019.

Clinical Outcomes

Clinical Outcomes

Outstanding evidence across trials

Button
Real-World Studies

Real-World Studies

Low event rates in real-world studies

Button
Early Healing

Early Healing

Advanced design for optimal healing

Button
Top